This study is testing a new treatment called cretostimogene to see if it can prevent intermediate-risk bladder cancer from returning after tumor removal surgery. About 367 participants will be randomly assigned to receive either the new treatment or standard observation with regu…
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC